Scopio’s technology utilizes Deep Learning AI technology and high-definition digital scans of blood samples in order to accurately analyze blood tests more efficiently.
Today, if a hematologist wanted to dive into the exact organization and structure of your blood cells, they’d probably need a microscope in a lab. Scopio, an Israel-based startup that just closed a $50 million Series C round, argues that soon, a lot of that work could be done with nothing more than a laptop. […]
Scopio Labs secured $50M in series C funding, which the company will use to scale manufacturing of its FDA-cleared imaging and AI analysis platform to support the shift to fully telehematology.